Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.92B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 1.27M
Average 1.84M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A14 analysts |
| Net Income | N/A | N/A | N/A | N/A14 analysts |
| EBIT | N/A | N/A | N/A | N/A14 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Neurocrine Biosciences, Inc. NASDAQ:NBIX | $16.94B | $167.40 | Undervalued | 23.8 | +12.67% |
Praxis Precision Medicines, Inc. NASDAQ:PRAX | $9.17B | $328.13 | Not rated | -25.0 | +89.47% |
Ionis Pharmaceuticals, Inc. NASDAQ:IONS | $4.84B | $29.06 | Not rated | -37.5 | -62.77% |
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX | $3.89B | $30.29 | Not rated | -11.3 | +93.07% |
Biohaven Ltd. NYSE:BHVN | $2.09B | $13.82 | Not rated | -3.1 | +41.74% |
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP | $1.25B | $26.15 | Not rated | -16.2 | -12.14% |
Alector, Inc. NASDAQ:ALEC | $378.15M | $2.54 | Not rated | -1.4 | +91.67% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -85.30% |
Cognition Therapeutics, Inc. NASDAQ:CGTX | $64.65M | $0.68 | Not rated | -6.4 | -54.84% |
ProMIS Neurosciences, Inc. NASDAQ:PMN | $29.50M | $3.29 | Not rated | -0.6 | +16.02% |
Continue the stock analysis
Jump to another research area for this company.